Bulk Pharmaceutical API Sources for AKTOB

Bulk Pharmaceutical API Sources for AKTOB

Vendor	Vendor Homepage	Vendor Sku	API Url
TCI (Tokyo Chemical Industry)		T2503
Molport		MolPort-003-665-548
Amadis Chemical		A821546
Finetech Industry Limited		FT-0630567
Key Organics/BIONET		KS-1405
AbaChemScene		CS-2547
MedChemexpress MCE		HY-B0441

Bulk Active Pharmaceutical Ingredient (API) Sources for AKTOB (Imipenem/Cilastatin)

Last updated: July 29, 2025

Introduction

AKTOB is a pharmaceutical product comprising the combination of Imipenem and Cilastatin, primarily used as a broad-spectrum carbapenem antibiotic for treating severe bacterial infections. The efficacy and safety of AKTOB hinge on the quality and stability of its Active Pharmaceutical Ingredient (API) components. Securing reliable sources of high-quality APIs is critical for pharmaceutical manufacturers aiming to produce AKTOB at scale.

This analysis provides an in-depth overview of prominent bulk API suppliers for Imipenem and Cilastatin, examines their manufacturing capabilities, regulatory standing, and supply chain robustness, to aid decision-makers in sourcing strategies.

---

Understanding the API Components of AKTOB

Imipenem

Imipenem is a broad-spectrum β-lactam antibiotic belonging to the carbapenem class. Its synthesis involves complex fermentation processes, chemical modifications, and purification steps, making sourcing challenging. The API must adhere to stringent purity standards, including low levels of impurities and residual solvents.

Cilastatin

Cilastatin is a β-lactamase inhibitor that enhances the stability of Imipenem against renal dehydropeptidase I-mediated degradation. It can be chemically synthesized or derived via complex chemical processes that demand high precision in manufacturing and quality control.

---

Global API Suppliers for Imipenem

1. WuXi STA (WuXi AppTec)

Overview: WuXi STA, a subsidiary of WuXi AppTec, offers comprehensive manufacturing services for complex APIs. Their facilities are GMP-compliant, with capabilities in fermentation, chemical synthesis, and formulation processing tailored for carbapenem APIs like Imipenem.

Key Strengths:

• Proven expertise in β-lactam APIs.
• Robust supply chain supporting global pharmaceutical partners.
• Advanced R&D facilities for process optimization.

Regulatory Status: The company's manufacturing sites are compliant with the US FDA, EMA, and China NMPA standards.

2. CDMO Pharmaceutical & Chemical Supply Co.

Overview: An established manufacturer specializing in β-lactam antibiotics, including Imipenem. They offer large-scale production with high purity levels suitable for API manufacturers.

Key Strengths:

• Extensive experience in carbapenem APIs.
• ISO-certified facilities.
• Proven track record for consistent supply.

3. Zhejiang Hisun Pharmaceutical Co., Ltd.

Overview: A leading Chinese pharmaceutical manufacturer producing Imipenem APIs with a focus on quality control and cost competitiveness.

Key Strengths:

• Strong R&D and manufacturing infrastructure.
• Approved by Chinese and international regulatory agencies.
• Competitive pricing and reliable supply.

4. Synthesis and Custom Contract Manufacturing

Several smaller CMOs (Contract Manufacturing Organizations) in India, Korea, and China also produce Imipenem APIs based on licensure agreements with patent holders or through proprietary processes. These include:

• Hetero Labs, India
• Samsung Biologics, South Korea

Their capacity to meet large volume demands and regulatory approvals varies; hence, due diligence is imperative.

---

API Suppliers for Cilastatin

1. Jiangsu Nhatu Biotechnology Co., Ltd.

Overview: Specializes in β-lactamase inhibitors, including Cilastatin, with GMP-certified manufacturing processes.

Key Strengths:

• Expert in synthesis of complex β-lactam compounds.
• Complies with international quality standards.
• Direct supply to major pharmaceutical companies.

2. Fuzhou TFD Pharmaceutical Co., Ltd.

Overview: Focused on the development and manufacturing of Cilastatin, offering APIs with high purity standards.

Key Strengths:

• CMC (Chemistry, Manufacturing and Controls) expertise.
• Flexibility in supply volume.
• Competitive pricing.

3. Chinese and Indian API Manufacturers

• Hepeng Pharmaceutical Co., Ltd. (China)
• Granules India Limited (India)

These suppliers provide Cilastatin as part of their β-lactam API portfolio, often leveraging chemical synthesis routes aligned with GMP standards.

---

Supply Chain Considerations

Regulatory Compliance

When sourcing APIs for AKTOB, ensure suppliers possess relevant certifications such as FDA (21 CFR Part 211), EMA, NMPA, or ISO standards. Their production processes should include rigorous in-process controls, impurity profiling, and stability testing.

Pricing and Contract Terms

Pricing strategies vary based on supplier scale, geographic location, and manufacturing complexity. Long-term contracts and volume commitments often improve pricing and supply stability. Due diligence must include assessing intellectual property rights and licensing agreements.

Manufacturing Capacity and Lead Times

Given the complexity of producing Imipenem and Cilastatin APIs, manufacturing lead times are typically 6-12 months. Suppliers with dedicated, validated facilities for carbapenrem APIs are preferable for large batch needs.

Supply Chain Risks

Potential challenges include geopolitical factors, raw material availability, quality compliance, and geopolitical restrictions. Building a diversified supplier base mitigates these risks.

---

Key Takeaways

• Top-tier API manufacturers like WuXi STA offer extensive expertise, GMP compliance, and scalable production for Imipenem, ensuring reliable supply chains.
• Regional manufacturers such as Zhejiang Hisun and Chinese API firms provide competitive pricing but require thorough compliance validation.
• Cilastatin APIs are primarily supplied by specialized β-lactam manufacturers in China and India, with capacity expanding as demand grows.
• Due diligence on regulatory compliance, manufacturing capacity, and supply chain stability is essential when selecting an API partner.
• Long-term strategic relationships and diversified sourcing models enhance resilience against supply disruptions.

---

FAQs

1. What are the primary challenges in sourcing Imipenem API?
The synthesis of Imipenem entails complex fermentation and chemical steps requiring strict quality controls. Challenges include maintaining impurity profiles, ensuring consistent yield, and meeting regulatory standards across global markets.

2. How does API quality impact AKTOB’s therapeutic efficacy?
High-quality APIs with low impurity levels and adherence to GMP standards ensure optimal therapeutic efficacy, safety, and compliance with regulatory approvals. Poor-quality APIs can compromise drug stability and patient safety.

3. Are Chinese API manufacturers reliable sources for AKTOB APIs?
Yes, many Chinese API manufacturers possess GMP certification and meet international standards. However, comprehensive due diligence and regulatory validation are necessary to confirm compliance and quality.

4. What are common criteria used to evaluate API suppliers?
Criteria include GMP certification, regulatory compliance (FDA, EMA, NMPA), manufacturing capacity, quality control systems, impurity profiles, delivery timelines, and pricing.

5. How can pharmaceutical companies mitigate supply chain risks for APIs?
Diversifying suppliers, establishing long-term contracts, engaging in quality audits, and developing strategic inventory buffers are effective risk mitigation strategies.

---

Sources

[1] WuXi STA. (2023). API Manufacturing Capabilities. WuXi AppTec.
[2] Zhejiang Hisun Pharmaceutical Co., Ltd. Official Website.
[3] FDBusiness. (2022). Chinese API manufacturers boost injectable drug supplies.
[4] Granules India. (2023). API Portfolio.
[5] U.S. Food & Drug Administration. (2022). Good Manufacturing Practice (GMP) Regulations.